Inquiry
mRNA Structural Characterization Service
This service is for Research Use Only, not intended for any clinical use.
Platforms
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform
Featured Platforms
Featured Services
GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010)
GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011)
GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012)
GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014)
Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015)
Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016)
Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017)
GalNAc-L96-OH (Cat#: X24-11-YM018)
GalNAc-L96-TEA (Cat#: X24-11-YM019)
Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036)
A2G2 N-Glycan (Cat#: X23-03-YW037)
A2G2S2 N-Glycan (Cat#: X23-03-YW038)
A2 N-Glycan (Cat#: X23-03-YW039)
A2[6]G1 N-Glycan (Cat#: X23-03-YW040)
M3 N-Glycan (Cat#: X23-03-YW041)
A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)
Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178)
Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179)
Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180)
Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181)
Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182)
T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192)
T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193)
Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)
Blood group A trisaccharide (Cat#: XCO0060Q)
Blood group B trisaccharide (Cat#: XCO0068Q)
Blood group H disaccharide (Cat#: XCO0074Q)
Lewis A trisaccharide (Cat#: XCO0079Q)
3'-Sulfated lewis A (Cat#: XCO0080Q)
Lewis B tetrasaccharide (Cat#: XCO0083Q)
Lewis X trisaccharide (Cat#: XCO0085Q)
Lewis Y tetrasaccharide (Cat#: XCO0088Q)
Lacto-N-biose (Cat#: XCO0089Q)
2'-Fucosyllactose (Cat#: XCO0091Q)
3-Fucosyllactose (Cat#: XCO0092Q)
Lactodifucotetraose (Cat#: XCO0093Q)
Lacto-N-triose I (Cat#: XCO0094Q)
3'-Sialyllactose sodium salt (Cat#: XCO0096Q)
6'-Sialyllactose sodium salt (Cat#: XCO0098Q)
3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)
Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478)
FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480)
TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481)
Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482)
Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598)
Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611)
Heparin disaccharide I-A (Cat#: X22-11-ZQ662)
Chondroitine sulfate (Cat#: X23-04-XQ1118)
GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005)
GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006)
GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007)
GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008)
Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037)
Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038)
Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039)
Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)
GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101)
GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112)
LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118)
Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131)
Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146)
Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162)
Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175)
nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)
Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119)
Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003)
Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004)
Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005)
Succinyl-γ-cyclodextrin (Cat#: X23-11-B006)
ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007)
β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008)
γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)
Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273)
Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279)
FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280)
FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283)
TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287)
FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291)
Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377)
TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383)
Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)
Online Inquiry